236 related articles for article (PubMed ID: 35997509)
41. Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
Hishinuma E; Narita Y; Saito S; Maekawa M; Akai F; Nakanishi Y; Yasuda J; Nagasaki M; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2018 Aug; 46(8):1083-1090. PubMed ID: 29769267
[TBL] [Abstract][Full Text] [Related]
42. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
[TBL] [Abstract][Full Text] [Related]
43. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.
Offer SM; Fossum CC; Wegner NJ; Stuflesser AJ; Butterfield GL; Diasio RB
Cancer Res; 2014 May; 74(9):2545-54. PubMed ID: 24648345
[TBL] [Abstract][Full Text] [Related]
44. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
45. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
46. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
47. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
[TBL] [Abstract][Full Text] [Related]
48. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
49. Renal impairment and DPD testing: Watch out for false-positive results!
Carriat L; Quaranta S; Solas C; Rony M; Ciccolini J
Br J Clin Pharmacol; 2022 Nov; 88(11):4928-4932. PubMed ID: 35939355
[TBL] [Abstract][Full Text] [Related]
50. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
He YF; Wei W; Zhang X; Li YH; Li S; Wang FH; Lin XB; Li ZM; Zhang DS; Huang HQ; Hu B; Jiang WQ
J Clin Pharm Ther; 2008 Jun; 33(3):307-14. PubMed ID: 18452418
[TBL] [Abstract][Full Text] [Related]
51. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
52. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
53. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
54. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Ezzeldin H; Diasio R
Clin Colorectal Cancer; 2004 Sep; 4(3):181-9. PubMed ID: 15377401
[TBL] [Abstract][Full Text] [Related]
55. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
56. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
Del Re M; Restante G; Di Paolo A; Crucitta S; Rofi E; Danesi R
Curr Pharm Des; 2017; 23(14):2028-2034. PubMed ID: 28128059
[TBL] [Abstract][Full Text] [Related]
58. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
Paré L; Paez D; Salazar J; Del Rio E; Tizzano E; Marcuello E; Baiget M
Br J Clin Pharmacol; 2010 Aug; 70(2):268-72. PubMed ID: 20653680
[TBL] [Abstract][Full Text] [Related]
59. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
60. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]